Oculis Holding AG
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Riad Sherif
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Bahnhofstrasse 7 Zug Switzerland 6300
- IPO Date
- May 18, 2021
- CIK
- 0001953530
- Website
- oculis.com
- Similar Companies
- Business
- Oculis Holding AG (Nasdaq: OCS) is a global biopharmaceutical company focused on developing transformative eye therapies to address unmet medical needs in ophthalmology. The company offers a pipeline of investigational product candidates, including OCS-01, a topical eye drop formulation of dexamethasone for the treatment of diabetic macular edema; OCS-02, a topical eye drop formulation of meloxicam for the treatment of dry eye disease and post-operative inflammation and pain; OCS-05, a topical eye drop formulation of lanosterol for the treatment of presbyopia; and OCS-09, a biologic targeting neurotrophic keratitis, among others. These therapies leverage Oculis's proprietary soluble NSAID platform and other advanced delivery technologies to improve efficacy, safety, and patient compliance in anterior and posterior segment eye diseases. Oculis operates primarily in the biopharmaceutical industry, targeting patients with retinal, corneal, and inflammatory eye conditions through clinical-stage development and potential commercialization. Founded in 2018 and headquartered in Lausanne, Switzerland, with additional operations in the United States and Europe, the company maintains subsidiaries including Oculis Vision Sciences Inc. in the U.S. In recent developments, Oculis reported positive topline results from its Phase 3 DIAMOND Phase 3 trial of OCS-01 in May 2025, demonstrating statistically significant and clinically meaningful improvements in best-corrected visual acuity in patients with diabetic macular edema.[web:previous] The company also advanced OCS-02 into Phase 2 trials for dry eye disease and secured a strategic collaboration with a leading contract development and manufacturing organization in late 2024 to support scale-up for Phase 3 readiness. Additionally, Oculis completed a successful equity financing round in Q1 2025, raising approximately $100 million to fund pipeline progression and operational expansion into key markets. These milestones reflect Oculis's strategic shift toward late-stage clinical execution and preparation for regulatory submissions in major jurisdictions including the U.S. and Europe.[web:previous]
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)
OCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud Violations
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Reports Q1 2026 Financial Results and Provides Company Update
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting